Esta semana hemos sabido que el primer estudio #IMMUNOMICSVHIO, codirigido por Rodrigo Toledo y Elena Garralda, demuestra que la biopsia líquida ultrasensible puede predecir y monitorizar la respuesta a la inmunoterapia en cánceres avanzados.
➡️ https://t.co/mYKsXZyiI4
#CAIMI #UITM
New paper from the @RToledoLab is out !
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy https://t.co/v4mT3yWCp6
I also had the rare (and fun) opportunity to tell an author their work was going to be on the cover of an upcoming issue when I met @RToledoLab at #AACR25! 😊
Featured on the cover: Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes https://t.co/HC39yqh8ZC
By Carlota Arenillas, @RToledoLab, and colleagues @VHIO
Now online in @CD_AACR: Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes - by Carlota Arenillas, @RToledoLab, and colleagues https://t.co/zpBGcp5PSz @VHIO
This year amazing @goharmonisation#ENSAT2023 meeting has come to an end. Thank you🙏 @DarkoKastelan and the entire local organising committee for great three days of science and networking in a beautiful location 👏 See you all next year in Palma de Maiorca 😊
Predictive Impact of mRNF43 in MSS mBRAFV600E mCRC Treated With Target Therapy or CTx
@JCOPO_ASCO
https://t.co/8UtvD4oYAd
👉pMMR/MSS mBRAFV600E mCRC benefit from TT vs CT independently of RNF43 mutational
👉Nevertheless, intersting efficacy in mRNF43 pts...
@myESMO@OncoAlert
Enhorabuena‼️ @RToledoLab recibe una de las Ayudas para la Investigación de la @APheipas para investigar la utilidad de la biopsia líquida en un grupo de tumores raros.
➕ https://t.co/SsfSl9Q44z